These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 29948641)

  • 1. [
    Provost C; Rozenblum-Beddok L; Nataf V; Merabtene F; Prignon A; Talbot JN
    Mol Imaging Biol; 2019 Apr; 21(2):297-305. PubMed ID: 29948641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amino acid PET tracers are reliable markers of treatment responses to single-agent or combination therapies including temozolomide, interferon-β, and/or bevacizumab for glioblastoma.
    Ono T; Sasajima T; Doi Y; Oka S; Ono M; Kanagawa M; Baden A; Mizoi K; Shimizu H
    Nucl Med Biol; 2015 Jul; 42(7):598-607. PubMed ID: 25892210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of two new angiogenesis PET tracers 68Ga-NODAGA-E[c(RGDyK)]2 and (64)Cu-NODAGA-E[c(RGDyK)]2; in vivo imaging studies in human xenograft tumors.
    Oxboel J; Brandt-Larsen M; Schjoeth-Eskesen C; Myschetzky R; El-Ali HH; Madsen J; Kjaer A
    Nucl Med Biol; 2014 Mar; 41(3):259-67. PubMed ID: 24417983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of glioblastoma response to temozolomide combined with bevacizumab based on μMRI and μPET imaging reveals [18F]-fluoro-L-thymidine as an early and robust predictive marker for treatment efficacy.
    Corroyer-Dulmont A; Pérès EA; Petit E; Guillamo JS; Varoqueaux N; Roussel S; Toutain J; Divoux D; MacKenzie ET; Delamare J; Ibazizène M; Lecocq M; Jacobs AH; Barré L; Bernaudin M; Valable S
    Neuro Oncol; 2013 Jan; 15(1):41-56. PubMed ID: 23115160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does imaging αvβ3 integrin expression with PET detect changes in angiogenesis during bevacizumab therapy?
    Rylova SN; Barnucz E; Fani M; Braun F; Werner M; Lassmann S; Maecke HR; Weber WA
    J Nucl Med; 2014 Nov; 55(11):1878-84. PubMed ID: 25278514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early assessment of the efficacy of temozolomide chemotherapy in experimental glioblastoma using [18F]FLT-PET imaging.
    Viel T; Schelhaas S; Wagner S; Wachsmuth L; Schwegmann K; Kuhlmann M; Faber C; Kopka K; Schäfers M; Jacobs AH
    PLoS One; 2013; 8(7):e67911. PubMed ID: 23861829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison and evaluation of two RGD peptides labelled with
    Provost C; Prignon A; Rozenblum-Beddok L; Bruyer Q; Dumont S; Merabtene F; Nataf V; Bouteiller C; Talbot JN
    Oncotarget; 2018 Apr; 9(27):19307-19316. PubMed ID: 29721204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 68Ga-DOTATOC and FDG PET Imaging of Preclinical Neuroblastoma Models.
    Provost C; Prignon A; Cazes A; Combaret V; Delattre O; Janoueix-Lerosey I; Montravers F; Talbot JN
    Anticancer Res; 2016 Sep; 36(9):4459-66. PubMed ID: 27630282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical Evaluation of Radiolabeled Peptides for PET Imaging of Glioblastoma Multiforme.
    Novy Z; Stepankova J; Hola M; Flasarova D; Popper M; Petrik M
    Molecules; 2019 Jul; 24(13):. PubMed ID: 31288488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. (68)Ga-labeled 3PRGD2 for dual PET and Cerenkov luminescence imaging of orthotopic human glioblastoma.
    Fan D; Zhang X; Zhong L; Liu X; Sun Y; Zhao H; Jia B; Liu Z; Zhu Z; Shi J; Wang F
    Bioconjug Chem; 2015 Jun; 26(6):1054-60. PubMed ID: 25853280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulsed versus conventional radiation therapy in combination with temozolomide in a murine orthotopic model of glioblastoma multiforme.
    Lee DY; Chunta JL; Park SS; Huang J; Martinez AA; Grills IS; Krueger SA; Wilson GD; Marples B
    Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):978-85. PubMed ID: 23845846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel (64)Cu- and (68)Ga-labeled RGD conjugates show improved PET imaging of α(ν)β(3) integrin expression and facile radiosynthesis.
    Dumont RA; Deininger F; Haubner R; Maecke HR; Weber WA; Fani M
    J Nucl Med; 2011 Aug; 52(8):1276-84. PubMed ID: 21764795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of Early Response Monitoring and Prediction of Cancer Antiangiogenesis Therapy via Noninvasive PET Molecular Imaging Strategies of Multifactorial Bioparameters.
    Bao X; Wang MW; Luo JM; Wang SY; Zhang YP; Zhang YJ
    Theranostics; 2016; 6(12):2084-2098. PubMed ID: 27698942
    [No Abstract]   [Full Text] [Related]  

  • 14. PET imaging of
    Isal S; Pierson J; Imbert L; Clement A; Collet C; Pinel S; Veran N; Reinhard A; Poussier S; Gauchotte G; Frezier S; Karcher G; Marie PY; Maskali F
    EJNMMI Res; 2018 Jun; 8(1):51. PubMed ID: 29904818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanistic interrogation of combination bevacizumab/dual PI3K/mTOR inhibitor response in glioblastoma implementing novel MR and PET imaging biomarkers.
    O'Halloran PJ; Viel T; Murray DW; Wachsmuth L; Schwegmann K; Wagner S; Kopka K; Jarzabek MA; Dicker P; Hermann S; Faber C; Klasen T; Schäfers M; O'Brien D; Prehn JH; Jacobs AH; Byrne AT
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1673-83. PubMed ID: 26975402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma Patients.
    Molina D; Pérez-Beteta J; Martínez-González A; Sepúlveda JM; Peralta S; Gil-Gil MJ; Reynes G; Herrero A; De Las Peñas R; Luque R; Capellades J; Balaña C; Pérez-García VM
    PLoS One; 2016; 11(8):e0161484. PubMed ID: 27557121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET imaging with [⁶⁸Ga]NOTA-RGD for prostate cancer: a comparative study with [¹⁸F]fluorodeoxyglucose and [¹⁸F]fluoroethylcholine.
    Israel I; Richter D; Stritzker J; van Ooschot M; Donat U; Buck AK; Samnick S
    Curr Cancer Drug Targets; 2014; 14(4):371-9. PubMed ID: 24720338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging of α
    Grönman M; Tarkia M; Kiviniemi T; Halonen P; Kuivanen A; Savunen T; Tolvanen T; Teuho J; Käkelä M; Metsälä O; Pietilä M; Saukko P; Ylä-Herttuala S; Knuuti J; Roivainen A; Saraste A
    J Transl Med; 2017 Jun; 15(1):144. PubMed ID: 28629432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Voxel-Wise Analysis of Fluoroethyltyrosine PET and MRI in the Assessment of Recurrent Glioblastoma During Antiangiogenic Therapy.
    George E; Kijewski MF; Dubey S; Belanger AP; Reardon DA; Wen PY; Kesari S; Horky L; Park MA; Huang RY
    AJR Am J Roentgenol; 2018 Dec; 211(6):1342-1347. PubMed ID: 30332289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Ga-68-Labeled Fusarinine C-Based Multivalent RGD Conjugates and [(68)Ga]NODAGA-RGD-In Vivo Imaging Studies in Human Xenograft Tumors.
    Zhai C; Franssen GM; Petrik M; Laverman P; Summer D; Rangger C; Haubner R; Haas H; Decristoforo C
    Mol Imaging Biol; 2016 Oct; 18(5):758-67. PubMed ID: 26905697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.